These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17624233)

  • 1. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy.
    Rubin RR; Peyrot M
    Curr Med Res Opin; 2007 Aug; 23(8):1919-29. PubMed ID: 17624233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric properties of an instrument for assessing treatment satisfaction associated with pramlintide use.
    Rubin RR; Peyrot M
    Diabetes Educ; 2009; 35(1):136-46. PubMed ID: 19244569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.
    Peyrot M; Rubin RR; Polonsky WH; Best JH
    Curr Med Res Opin; 2010 May; 26(5):1047-54. PubMed ID: 20199136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.
    Marrero DG; Crean J; Zhang B; Kellmeyer T; Gloster M; Herrmann K; Rubin R; Fineberg N; Kolterman O
    Diabetes Care; 2007 Feb; 30(2):210-6. PubMed ID: 17259483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight.
    Karl D; Philis-Tsimikas A; Darsow T; Lorenzi G; Kellmeyer T; Lutz K; Wang Y; Frias JP
    Diabetes Technol Ther; 2007 Apr; 9(2):191-9. PubMed ID: 17425446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
    Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
    Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and harms of the hypoglycemic agent pramlintide in diabetes mellitus.
    Lee NJ; Norris SL; Thakurta S
    Ann Fam Med; 2010; 8(6):542-9. PubMed ID: 21060125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin.
    Riddle M; Frias J; Zhang B; Maier H; Brown C; Lutz K; Kolterman O
    Diabetes Care; 2007 Nov; 30(11):2794-9. PubMed ID: 17698615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes.
    Riddle M; Pencek R; Charenkavanich S; Lutz K; Wilhelm K; Porter L
    Diabetes Care; 2009 Sep; 32(9):1577-82. PubMed ID: 19502544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: a pooled post hoc analysis.
    Maggs D; Shen L; Strobel S; Brown D; Kolterman O; Weyer C
    Metabolism; 2003 Dec; 52(12):1638-42. PubMed ID: 14669170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.
    Edelman S; Garg S; Frias J; Maggs D; Wang Y; Zhang B; Strobel S; Lutz K; Kolterman O
    Diabetes Care; 2006 Oct; 29(10):2189-95. PubMed ID: 17003291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
    Pullman J; Darsow T; Frias JP
    Vasc Health Risk Manag; 2006; 2(3):203-12. PubMed ID: 17326327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
    Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG
    Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does treatment satisfaction work?: Modeling determinants of treatment satisfaction and preference.
    Peyrot M; Rubin RR
    Diabetes Care; 2009 Aug; 32(8):1411-7. PubMed ID: 19470837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.